Basilea publishes investor presentation on anti-infectives strategy, pipeline and hospital brands Cresemba, Zevtera

(AWP Alliance News) - Basilea Pharmaceutica AG highlighted Cresemba and Zevtera as its two revenue-generating hospital anti-infective brands, positioning Cresemba as the global value market leader with USD 782 million in moving annual total sales for April 2025 to March 2026, up 27% year on year. The presentation flagged a continued growth runway for Cresemba in the US through Q4 2027, in Europe through H2 2028, with Japan and other markets extending beyond 2028. Basilea also pointed to Zevtera's US launch in July 2025 via Innoviva Specialty Therapeutics, citing early formulary wins and US market exclusivity through April 2034. It outlined late-stage pipeline priorities in fosmanogepix and ceftibuten-ledaborbactam, with the latter's phase 3 program in complicated urinary tract infections expected to start in early 2027. Basilea reported about USD 440 million in awarded non-dilutive funding, including about USD 165 million referenced as "out of which," as part of its capital-efficient partnering model.

https://docs.publicnow.com/E8EF9AF3D83117C0CCF0622601B77903EF3F0AD8

Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.